Nimbus Data Systems, one of the first storage vendors to bring Flash-based storage arrays to market, on Tuesday unveiled its first formal channel program as part of a move to make solution providers ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nimbus Therapeutics, a biotech that integrates computational chemistry and other advanced technologies to design breakthrough medicines and transform drug ...

Gilead Sciences Inc. GILD has come up with two important corporate announcements – the company’s third tenofovir alafenamide (TAF)-based HIV drug, Descovy, has gained FDA approval and it has struck ...

FOSTER CITY, Calif. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Gilead Sciences, Inc. (NASDAQ:GILD) and Nimbus Therapeutics, LLC today announced that the companies have signed a definitive agreement under ...

Nimbus Therapeutics has raised $105 million to put its allosteric TYK2 inhibitor through a clutch of phase 2 clinical trials. The multifront midphase program is designed to determine whether the drug ...

Sotyktu (deucravacitinib), the tyrosine kinase 2 (TYK2) inhibitor for psoriasis from Bristol Myers Squibb Co., is “a good first-in-class” drug, said Nimbus Therapeutics LLC CEO Jeb Keiper, but his ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nimbus Therapeutics, a biotechnology company designing breakthrough medicines through its powerful computational discovery engine, today announced initiation of a ...

Nimbus Therapeutics said yesterday it has won a $200 million milestone payment from Gilead Sciences based on progress in its clinical development of the allosteric acetyl-CoA carboxylase (ACC) ...

SOUTH SAN FRANCISCO, Calif., Jan. 10, 2012 /PRNewswire/ — Nimbus Data Systems, Inc., the leader in Sustainable Storage systems and software, today announced its FlashPoint Partner Program. This ...

Celgene and the computational chemistry company Nimbus Therapeutics are teaming up to advance R&D on small molecules that could treat a suite of immunology conditions. One Nimbus program is designing ...